Latest news

• NHS says Humira biosimilar deal will save £300m

  end. Amgen’s copy Amgevita and Samsung and Biogen’s Imraldi both gained full EU approval last year, and have been joined since by Hyrimoz from Novartis’ Sandoz division, Boehringer

• First Humira biosimilars reach EU market

  Also already launched is Samsung Bioepis and Biogen’s Imraldi is also close to launch in their first markets, while Amgen’s Amgevita, which was the first Humira biosimilar to get ... Imraldi. There is no word yet on the roll-out plans for

• Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab's OX40 candidate

  Amgen’s copy Amgevita and Samsung and Biogen’s Imraldi both gained full EU approval last year, giving them lots of time to prepare the market before they are permitted to

• Settlement clears path for Biogen, Samsung’s Humira biosimilar

  The three companies have reached a settlement in patent litigation that sets out definitive launch dates for the new Imraldi biosimilar, which was approved by the EMA last August, on both ... Imraldi hasn’t yet been approved by the FDA. A similar deal

• MSD launches EU’s first biosimilar Herceptin in UK

  Ontruzant was the fourth biosimilar developed by the Korean company to receive marketing authorisation in the EU, after Benepali (etanercept), Flixabi (infliximab), and Imraldi (adalimumab).